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Abstract:
Purpose: To test the influence of 1000 mg of quercetin (Q) with or without 120 mg of epigallocatechin 3-
gallate (EGCG), 400 mg of isoquercetin, and 400 mg of eicosapentaenoic acid and docosahexaenoic acid 
(Q–EGCG) on exercise performance, muscle mitochondrial biogenesis, and changes in measures of 
immunity and inflammation before and after a 3-d period of heavy exertion. Methods: Trained cyclists (N = 
39) were randomized to placebo (P), Q, or Q–EGCG and ingested supplements in a double-blinded fashion
for 2 wk before, during, and 1 wk after a 3-d period in which subjects cycled for 3 hIdj1 at È57% Wmax. 
Blood, saliva, and muscle biopsy samples were collected before and after 2 wk of supplementation and 
immediately after the exercise bout on the third day. Blood and saliva samples were also collected 14 h after 
exercise. Results: Two-week supplementation resulted in a significant increase in plasma quercetin for Q 
and Q–EGCG and granulocyte oxidative burst activity (GOBA) in Q–EGCG. Immediately after the third 
exercise bout, significant decreases for C-reactive protein (CRP), and plasma interleukin 6 (IL-6) and 
interleukin 10 (IL-10) were measured in Q–EGCG compared with P. Granulocyte colony-stimulating factor 
and CRP were reduced in Q–EGCG 14 h after exercise. No group differences were measured in muscle 
messenger RNA expression for peroxisome proliferator-activated receptor F coactivator >, citrate synthase, 
or cytochrome c. Conclusions: Two-week supplementation with Q–EGCG was effective in augmenting 
GOBA and in countering inflammation after 3 d of heavy exertion in trained cyclists.
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T 
he flavonoids are a group of diverse, low-molecular 
weight polyphenolic substances that occur naturally 
in plant foods. The structural complexity of flavo- 
noids has led to their subclassification as flavonols, 
flavones, flavanones, flavan-3-ols (and their oligomers, 
proanthocyanidins), isoflavones, and anthocyanins (34). 
They are present in significant amounts in many commonly 
consumed fruits, vegetables, grains, herbs, and beverages 
such as tea and fruit juices (7). Flavonoids are strong 
antioxidants in vitro, mainly because of their low redox 
potential and their capacity to donate several electrons or 
hydrogen atoms. 
Despite the strong antioxidant capacity of flavonoids, 
their antioxidant efficacy in vivo is limited by low 
absorption, short half-lives, and extensive first-pass metab- 
olism (2,22). In the intestinal mucosa and liver, flavonoids 
undergo glucuronidation, methylation, and sulfation. This 
biotransformation alters the physical properties of flavo- 
noids, making them more water soluble with weakened 
antioxidant and anti-inflammatory activity (2,3,20,33). 
Quercetin  (2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy- 
4H-chromen-4-one; molecular mass 302.236 gImolj1) is a 
flavonol that constitutes the aglycone of the plant glyco- 
sides rutin and quercitrin. Of all flavonoids, quercetin is 
among the most widespread, with broad-spectrum bioactive 
effects (2). These include anti-inflammatory (3,6,13,20), 
antipathogenic (9,31,36), and antioxidant activities (2,5,19); 
immunoregulatory influences (13,33); and central nervous 
system (1) and muscle mitochondrial biogenesis stimulatory 
effects (8). Common food sources of quercetin in the United 
States and in Europe are onions, apples, and various types 
of berries (7,22). Human subjects can absorb significant 
amounts of quercetin, with a reported half-life  ranging 
from 3.5 to 28 h (22,25). Long-term high-dose quercetin 
supplementation in rodents and humans has not been linked 
to any adverse effects (14,35), and epidemiological studies 
indicate that higher compared with lower quercetin intake 
from food is associated with reduced risk for ischemic heart 
disease, type 2 diabetes, asthma, and various types of 
cancer, including lung, colorectal, pancreatic, and prostate 
cancers (2,27). 
Endurance  athletes  undergoing  repeated  physiologic 
stress from training and competition may receive benefit 
 
from quercetin supplementation. Animal and human data 
indicate that quercetin improves endurance  performance 
and lowers infection risk (8,21,31). In two studies with 
human athletes, however, 3 wk of 1000-mg quercetinIdj1 
supplementation failed to counter exercise-induced alter- 
ations in immunity, inflammation, and oxidative stress 
(15,23,29–31). One potential weakness of these human 
studies was that the quercetin supplements were ingested 
10–24 h before the completion of exercise, a period that 
may have been too long given the half-life of quercetin 
(25). Also, there is increasing support for coingestion of 
quercetin with other flavonoids and food components to 
improve and extend quercetin’s bioavailability and bioactive 
effects (4,5,16,17,24,36). These include the flavonoid epi- 
gallocatechin 3-gallate (EGCG)  from tea (12,24,26),  iso- 
quercetin (quercetin-3-glucose or hirsutrin), which is the 
glycosylated form of quercetin in onions and other foods 
(2,4,22), N3-polyunsaturated fatty acids (N3-PUFA) such as 
eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) (4), and the nutrients vitamin C and folate (17,36). 
This study extends our previous work in endurance 
athletes by testing the influence of a quercetin supplement 
with or without EGCG, isoquercetin, EPA, DHA, vitamin 
C, and folic acid on chronic and acute measures of immune 
function, inflammation, and mitochondrial biogenesis be- 
fore and after a 3-d period of intensified exercise. Supple- 
ments were ingested twice daily for 2 wk before, during, 
and 1 wk after the 3-d period of exercise, with the last daily 
dose taken 1 h before exercise to ensure high plasma 
quercetin levels. The outcome measures chosen for this 
study are similar to those used in previous quercetin 
projects by our research group to allow comparisons of 
results (15,29,30). 
 
METHODS 
Subjects. Thirty-nine trained male (n = 32) and female 
(n = 7) cyclists were recruited and tested as experimental 
subjects through local and collegiate cycling clubs. Written 
informed consent was obtained from each subject, and the 
experimental procedures were approved by the institutional 
review board of Appalachian State University. 
Research design. Within 1 wk before the start of 
supplementation, subjects reported to the university’s Human 
Performance Lab for orientation and measurement of cardio- 
respiratory fitness. V̇  O2max  was determined using a graded 
maximal protocol (25-W increase every 2 min starting at 
150 W), with the subjects using their own bicycles on 
CompuTraineri Pro Model 8001 trainers (RacerMate, 
Seattle, WA). Oxygen uptake and ventilation were measured 
using the MedGraphics CPX metabolic system (Med- 
Graphics Corporation, St. Paul, MN). HR was measured 
using a chest HR monitor (Polar Electro, Inc, Woodbury, 
NY). Basic demographic and training data were obtained 
through a questionnaire. Body composition was measured 
using hydrostatic weighing as previously described (31). 
Subjects agreed to avoid the use of large-dose vitamin/ 
mineral supplements (more than 100% of recommended 
dietary allowances), herbs, and medications known to affect 
immune function during the entire study. During orienta- 
tion, a dietitian instructed the subjects to follow a diet 
moderate in carbohydrate (using a food list) during the 
weekend before and the 3-d intensified exercise period. At 
12:00–12:30 p.m. before each 3-h cycling bout, subjects 
ingested a standardized liquid meal (Boost Plus; Mead 
Johnson Nutritionals, Evansville, IN) at an energy level 
of 63 kJIkgj1 (15 kcalIkgj1). Boost Plus is a nutritionally 
complete, high-energy oral supplement with an energy 
density of 6.4 kJImLj1 (1.52 kcalImLj1) and 16% of 
energy as protein, 34% as fat, and 50% as carbohydrate. In 
quantities of 1000 mL, Boost Plus exceeds daily value 
recommendations for all major vitamins and minerals. No 
other food and beverage (other than water) was consumed 
from this meal until the end of the cycling bout. Subjects 
ingested 0.5 to 1 L of water per hour of cycling. 
The cyclists were randomized to quercetin (Q), quercetin– 
EGCG (Q–EGCG), or placebo (P) groups. Under double- 
blind procedures, subjects ingested four P, Q, or Q–EGCG 
soft chews per day (two in the morning at 7:00–8:00 a.m. and 
two in the afternoon at 2:00 p.m.) for 14 d before, during a 3-d 
period of intensified exercise, and 7 d after the training period 
(thus, a total of 24 d). The soft chew supplements were 
designed by Quercegen Pharma (Newton, MA) and prepared 
by Nutravail Technologies (Chantilly, VA). Each placebo soft 
chew contained brown rice syrup, evaporated cane juice, 
carnuba wax, natural flavors, gelatin, soy lecithin, palm oil, 
glycerin, xylitol, monoglyceride and diglyceride, corn starch, 
carrageenan, sucralose, and 20-kcal energy with citric acid to 
substitute for taste of vitamin C and FD&C yellow no. 5 and 
FD&C blue no. 1 to substitute for the quercetin color. Each 
Q-chew contained all P ingredients with 250 mg of quercetin, 
250 mg of vitamin C, 10 mg of niacinamide, and 200 Kg of 
folic acid. These nutrients were included in the Q-chew to 
facilitate quercetin absorption in the small intestine (personal 
communication; Quercegen Pharma). Each Q–EGCG chew 
contained all Q-chew ingredients with 30 mg of EGCG from 
green tea extract, 100 mg of isoquercetin, and 100 mg of N3- 
PUFA (55 mg of EPA and 45 mg DHA) from fish oil. These 
food components were included to improve quercetin 
bioavailability and extend its bioactive effects, as determined 
by experiments conducted by Quercegen Pharma (personal 
communication). 
Before and after the first 14 d of supplementation, 
subjects provided blood and saliva samples at 8:00 a.m. 
after an overnight fast and having avoided exercise training 
for at least 12 h and before having ingested supplements. 
Subjects then came to the laboratory for three consecutive 
days and cycled from 3:00 to 6:00 p.m. at È57% Wmax. 
During the test sessions, experimental subjects cycled using 
their own bicycles on CompuTraineri Pro Model 8001 
trainers (RacerMate) with the exercise load set at È57% 
Wmax,  as  in  a  previous  study  conducted  within  our 
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laboratory (31). Metabolic measurements were made every 
30 min of cycling using the MedGraphics CPX metabolic 
system (MedGraphics Corporation) to verify workload. 
Time trials (5, 10, and 20 km on days 1, 2, and 3, respec- 
tively) were inserted at the end of each cycling bout, with 
distances and workload monitored using  CompuTraineri 
MultiRider software (v.3.0; RacerMate). Blood and saliva 
samples were obtained immediately after completing the 
third 3-h exercise bout (6:00 p.m.) and then again 14 h later 
(8:00 a.m., overnight fasted, and having avoided supple- 
ments since 2:00 p.m. the previous day). Subjects continued 
ingestion of the supplements for seven additional days 
while training normally and being monitored for delayed 
onset of muscle soreness (DOMS). Subjects recorded 
muscle soreness during the 3 d of cycling and for a week 
afterward using a 10-point Likert scale (32). Cyclists were 
asked to supply a number that best described any general 
feeling of painful, sore, aching leg muscles using this scale: 
1 (no soreness), 2.5 (dull, vague ache), 4 (slight soreness), 
5.5 (more than slight soreness), 7 (sore), 8.5 (very sore), 
and 10 (unbearably sore). 
Blood samples, C-reactive protein, and creatine 
kinase. Blood samples were drawn from an antecubital vein 
with subjects in the supine position. Routine complete blood 
counts were performed by our clinical hematology laboratory 
using a Coulter STKS instrument (Coulter Electronics, 
Hialeah, FL) and provided hemoglobin and hematocrit for 
the determination of plasma volume change using the method 
of Dill and Costill (10). Other blood samples were centrifuged 
in sodium heparin or Ethylene diamine Tetra-acetic Acid 
(EDTA) tubes, and plasma was aliquoted and then stored at 
j80-C before plasma cytokine analysis. Serum C-reactive 
protein (CRP), and creatine kinase (CK) were measured in a 
clinical laboratory using an LX-20 clinical analyzer 
(Beckman, Brea, CA). 
Plasma quercetin. Total plasma quercetin (quercetin 
and its primary conjugates) was measured after solid-phase 
extraction via reversed-phase high performance liquid chro- 
matography (HPLC) with UV detection as previously de- 
scribed (29–31). Quercetin conjugates were hydrolyzed by 
incubating 500 KL of plasma aliquots with 10 KL of 10% 
DL-dithiothreitol solution, 50 KL of 0.58 M acetic acid, and 
50 KL of a mixture of A-glucuronidase/arylsulfatase and 
crude extract from Helix pomatia (Roche Diagnostics 
Corporation, Indianapolis, IN) for 2 h at 37-C. Chromatog- 
raphic analysis was performed using  the Ultimate 3000 
HPLC-PDA system (Dionex Corporation, Sunnyvale, CA) 
with a Gemini C18 column (Phenomenex, Torrance, CA). On 
the basis of the duplicate analysis of three quality control 
samples, with human plasma samples spiked with quercetin at 
concentrations of 1.0, 1.5, and 3.0 KmolILj1, the intra-assay 
coefficient of variation (CV) was 12.5%. 
Plasma cytokine, heat shock protein 70, and 
myeloperoxidase measurements. Enzyme-linked im- 
munosorbent assays were used, in accordance with the 
manufacturer  protocol,  to  measure  total  plasma  con- 
centrations of interleukin 1 receptor antagonist (IL-1RA), 
interleukin 6 (IL-6 and IL-6 high sensitivity), granulocyte 
colony-stimulating factor (G-CSF and G-CSF high sensi- 
tivity), granulocyte monocyte colony-stimulating factor 
(GM-CSF), monocyte chemoattractant protein 1 (MCP-1), 
myeloperoxidase (MPO), tumor necrosis factor > (TNF->), 
IL-10 (R&D Systems, Inc., Minneapolis, MN), IL-10 
ultrasensitive (BioSource International, Inc., Camarillo, 
CA), and heat shock protein 70 (HSP-70; Assay Designs, 
Inc, Ann Arbor, MI). All samples and provided standards 
were analyzed in duplicate. High-sensitivity kits were used 
to analyze all TNF-> and preexercise and recovery IL-6, 
IL-10, and G-CSF samples. The minimum detectable 
concentrations of IL-1RA, IL-6, IL-6 (high sensitivity), IL-
10, IL-10 (high sensitivity), G-CSF, G-CSF (high 
sensitivity), MCP-1, TNF->, GM-CSF, MPO, cortisol, and 
HSP-70 were G2.2 pgImLj1, G0.7 pgImLj1, G0.039 
pgImLj1, G3.9 pgImLj1, G0.2 pgImLj1, G20 pgImLj1, 
G0.80  pgImLj1,  G5.0  pgImLj1,  G0.106  pgImLj1,  G0.26 
pgImLj1, 0.100 ngImLj1, 0.1 KgIdLj1, and 0.09 ngImLj1, 
respectively. Preexercise and postexercise samples were 
analyzed on the same assay plate to decrease interkit assay 
variability, and the intra-assay CV for all variables was less 
than 10%. Data were analyzed with SOFTmax software 
(Molecular Devices, Sunnyvale, CA). 
Whole-blood polymorphonuclear oxidative burst 
activity assay. Polymorphonuclear (PMN) oxidative burst 
activity was measured in whole blood according to the 
procedures previously published by Nieman et al. (31). The 
mean fluorescence number was determined, and the PMN 
oxidative burst activity was calculated by subtracting the 
mean fluorescence intensity of the endogenous respiratory 
burst activity from the mean fluorescence intensity of the 
stimulated respiratory burst activity. The intra-assay CV 
was less than 15% for each time point. 
Salivary immunoglobulin A. Saliva was collected and 
stored, and volume and total protein were measured  as 
previously described (31). Salivary immunoglobulin A (sIgA) 
concentrations were measured using a quantitative indirect 
competitive immunoassay provided  by Salimetrics, LLC 
(State College, PA). All samples and standards were analyzed 
in duplicate, and the intra-assay CV was less than 10% for 
sIgA concentration across all time points. The minimum 
detectable concentration for the assay was G2.5 KgImLj1. 
Data are expressed as concentration of sIgA relative to total 
protein concentration (KgImgj1). 
Muscle biopsies. Muscle biopsies were obtained from 
the vastus lateralis before and after 2 wk of supplementa- 
tion. The postsupplementation biopsy was obtained È2 cm 
proximal from the presupplementation biopsy site. Muscle 
samples were collected from the opposite leg after exercise, 
with leg order randomly determined. Local anesthesia (2% 
xylocaine) was injected subcutaneously and intramuscu- 
larly. After a small incision (È0.5 cm), a muscle biopsy 
sample (È100 mg) was obtained using the percutaneous 
needle biopsy procedure modified to include suction (11). 
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 TABLE 1. Sub jects’ charact eristics and perfo rmance measu res (mean T SE).   
   Varia ble P ( = 12)     Q ( = 13)   Q– EGCG ( = 14)             
Baseline measures 
Age (yr) 26.3 T 1.7     26.8 T 2.6 28.1 T 2.8 0.876 
Body mass (kg) 72.0 T 4.0     72.6 T 3.8 71.8 T 2.9 0.987 
V̇ O2max      (mLIkgj1Iminj1) 60.2 T 1.8     61.4 T 2.3 60.3 T 2.2 0.906 
Powermax (W) 308 T 12.2    301 T 16.9 321 T 16.5     0.628 
HRmax    (beatsImin
j1) 189 T 2.7 187 T 2.4 184 T 2.0 0.261 
Body composition (% fat)   15.0 T 1.7     16.2 T 1.0 14.3 T 1.5 0.630 
Performance measures 
 
Mean power (W) 174 T 7.2 173 T 9.9 182 T 8.7 0.720 
Power (% Wmax) 56.5 T 0.5 57.5 T 0.6 56.6 T 0.6 0.458 
Mean HR (beatsIminj1) 147 T 3.8 145 T 1.4 144 T 2.2 0.576 
HR (% HRmax) 78.0 T 1.1 77.7 T 0.9 78.6 T 1.1 0.818 
Mean V̇ O2  (mLIminj1) 2670 T 92 2661 T 134 2721 T 133 0.931 
V̇ O2  (% V̇ O2max) 62.3 T 1.7 60.7 T 2.3 62.8 T 1.1 0.679 
       Time trials (min) 43.8 T 1.0     43.4 T 0.9         42.9 T 1.5       0.860    
Performance measures represent the mean of three exercise sessions. 
V̇ O2, volume of oxygen consumption. 
 
 
Muscle was trimmed of connective tissue and fat and was 
immediately frozen in liquid nitrogen. Samples were stored 
at j80-C until subsequent analysis. 
Muscle RNA isolation and complementary DNA 
synthesis. Skeletal muscle was homogenized under liquid 
nitrogen with a micropestle, and total RNA was extracted by 
using the guanidine thiocyanate method with TRIzol 
(Invitrogen, Carlsbad, CA). The extracted RNA was dis- 
solved in diethylpyrocarbonate-treated water and quantified 
spectrophotometrically at 260 nm. Intact RNA was con- 
firmed by denaturing agarose gel (1%) electrophoresis. RNA 
was reverse transcribed using the high-capacity complemen- 
tary DNA (cDNA) reverse transcription kit (Applied Bio- 
systems, Foster City, CA) according to the manufacturer’s 
protocol. 
Quantitative real-time polymerase chain reaction 
analysis. Briefly, 25 ng of cDNA was used in each reaction 
(TaqMan Gene Expression Assays; Applied Biosystems) as 
per manufacturer’s instructions. Relative expression levels 
of citrate synthase, cytochrome c oxidase  I, peroxisome 
proliferator-activated receptor F coactivator > (PGC-1>), 
and housekeeping gene glyceraldehyde-3-phosphate dehy- 
drogenase (GAPDH) were determined with predesigned, 
preoptimized gene-specific probe sets provided by Applied 
Biosystems (TaqMan Gene Expression Assays). Samples 
were loaded in a MicroAmp 96-well reaction plate and run 
in triplicate. Quantitative real-time polymerase chain reac- 
tion was performed on an ABI 7300 sequence detector. 
Data were analyzed using Applied Biosystems 7300 
sequence detection software v1.3.1. Relative messenger 
RNA (mRNA) levels were determined using the $$Ct 
method, with GAPDH serving as the as the endogenous 
control (18). 
Statistical analysis. Data are expressed as mean T SE. 
Data in Tables 1 and 4 were  compared  between  groups 
using one-way ANOVA. Data in Tables 2 and 3 and in 
Figures 1 to 4 were analyzed using a 3 (groups) x 4 (time 
points) repeated-measures ANOVA. The DOMS data in 
Figure 4 were analyzed using a 3 x 10 repeated-measures 
ANOVA. When Box’s M suggested that the assumptions 
necessary for the univariate approach were not tenable, the 
multivariate approach to repeated-measures ANOVA was 
used (Pillai’s trace). When interaction effects were P G 0.30 
(with this level chosen because of a mixture of chronic and 
acute changes across the four time points), the changes 
before and after at a given time point were calculated and 
compared between groups using Student’s t-tests, with 
significance set at P e 0.05. This data analysis  allowed 
group comparisons for three different effects: 2-wk chronic 
supplementation (before and after supplementation, 8:00 a.m., 
overnight-fasted), acute postexercise changes, and 14 h 
postexercise  recovery. 
 
RESULTS 
Subject characteristics and performance data for the 39 
cyclists randomized to P (n = 10 males, 2 females), Q (n = 11 
males, 2 females), and Q–EGCG (n = 11 males, 3 females) 
groups and completing all phases of the study are 
summarized in Table 1. Outcome data for male and female 
cyclists did not differ significantly and are presented to- 
gether for each group. 
 
TABLE 2. Blood leukocyte counts, CK, sIgA–protein ratio, and MPO. 
 
Variable Before  Supplementation After Supplementation After Exercise 14 h after Exercise 
Total blood leukocytes (109 Lj1)      
P 5.25 T 0.22 5.61 T 0.28 12.30 T 1.16 6.18 T 0.30 0.110 
Q 5.29 T 0.30 5.23 T 0.32 10.22 T 0.62 5.44 T 0.25*  
Q–EGCG 
CK  (UILj1) 
5.51 T 0.31 5.42 T 0.37 10.26 T 0.67 5.42 T 0.34*  
P 150 T 28.4 119 T 14.5 347 T 111 333 T 109 0.672 
Q 161 T 33.3 129 T 19.5 209 T 39.9 189 T 28.9  
Q–EGCG 149 T 18.4 156 T 28.2 379 T 157 323 T 101  
sIgA–protein  (KgImgj1)      
P 278 T 35.4 201 T 39.7 127 T 22.1 290 T 35.8 0.694 
Q 244 T 36.3 199 T 36.6 96.2 T 11.9 263 T 33.7  
Q–EGCG 
MPO (ngImLj1) 
272 T 33.8 280 T 31.1 172 T 24.6 301 T 31.4  
P 95.1 T 18.2 69.7 T 7.9 178 T 20.4 90.1 T 10.9 0.225 
Q 90.0 T 8.8 80.3 T 9.9 132 T 16.3 96.3 T 20.8  
Q–EGCG 112 T 19.9 58.5 T 8.3 141 T 33.8 86.6 T 10.2  
P value represents group (3) x time (4) interaction. Significant time effects were shown for all variables listed (P G 0.001). 
* P G 0.05, change from before supplementation compared with placebo. 
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TABLE 3. Plasma cytokine and HSP-70 levels before and after 2 wk of supplementation and immediately and 14 h after exercise. 
 
Variable Before  Supplementation After  Supplementation After Exercise 14 h after Exercise 
G-CSF (pgImLj1)      
P 25.2 T 1.4 26.1 T 2.6 36.3 T 4.1 39.2 T 5.1 0.016 
Q 25.2 T 1.2 26.6 T 1.7 34.2 T 3.4 27.1 T 1.8*  
Q–EGCG 26.1 T 2.7 29.0 T 4.4 27.2 T 3.5 24.0 T 1.8*  
IL-10 (pgImLj1)      
P 13.6 T 2.9 19.6 T 4.5 66.3 T 18.6 17.6 T 4.3 0.025 
Q 15.1 T 4.4 11.2 T 2.0 31.5 T 4.4* 22.3 T 6.1  
Q–EGCG 
MCP (pgImLj1) 
19.4 T 5.4 22.1 T 6.7 33.6 T 5.6* 16.1 T 4.3  
P 280 T 24.8 289 T 22.2 435 T 40.9 303 T 23.7 0.174 
Q 309 T 16.8 282 T 21.1 411 T 26.2 296 T 19.4  
Q–EGCG 284 T 18.0 290 T 13.5 370 T 24.2 293 T 13.1  
IL-1RA (pgImLj1)      
P 183 T 10.7 167 T 11.2 569 T 169 276 T 47.2 0.630 
Q 173 T 10.1 179 T 15.8 774 T 273 233 T 29.2  
Q–EGCG 191 T 27.8 226 T 61.9 458 T 161 181 T 15.2  
TNF-> (pgImLj1)      
P 3.38 T 0.58 2.61 T 0.26 2.37 T 0.40 2.65 T 0.41 0.427 
Q 4.40 T 0.58 3.47 T 0.39 2.21 T 0.24 2.36 T 0.31  
Q–EGCG 4.21 T 0.81 3.44 T 0.53 2.76 T 0.42 2.84 T 0.42  
HSP-70 (ngImLj1)      
P 1.89 T 0.47 1.68 T 0.31 2.77 T 0.37 1.85 T 0.43 0.734 
Q 1.88 T 0.37 1.99 T 0.44 2.35 T 0.28 1.76 T 0.32  
Q–EGCG 2.03 T 0.40 2.31 T 0.40 3.01 T 0.40 1.77 T 0.32  
P value represents group (3) x time (4) interaction. Significant time effects were shown for all variables listed (P G 0.001). 
* P G 0.05, change from before supplementation compared with placebo. 
 
No significant differences were found among groups for 
age, body composition, or maximal performance measures. 
Subjects (all combined) averaged 260 T 30.4 kmIwkj1 of 
cycling during the previous year and 0.65 T 0.04 h of 
training per day during the previous 18 d (off-season train- 
ing). Thus, the 3-d intensified exercise period (9-h exercise) 
represented a 3.6-fold increase in training duration per bout 
at this time of the year and a substantial increase overall in 
exercise workload and intensity. Subjects in all groups were 
able to maintain a mean power output of 56.9 T 0.6% Wmax 
at  an  oxygen  consumption  of  È62%  V̇  O2max   during  the 
exercise bouts (Table 1). Total time trial duration (sum of 
5-, 10-, and 20-km trials conducted during the last portion 
of each 3-h bout) did not differ among groups (Table 1). 
Plasma volume change did not differ among groups after 
 
 
 
FIGURE 1—Plasma quercetin before and after 2 wk of supplementa- 
tion, immediately after exercise after 3 d of cycling (3 hIdj1), and 14 h 
after exercise. Group x time interaction P value = 0.008. *P G 0.05, 
change from before supplementation compared with placebo. 
exercise on the third day and averaged less than 2% because 
of ingestion of 0.5–1.0 L of water per day of exercise (data 
not shown). 
After 2 wk of consuming two soft chew supplements at 
8:00 a.m. and 2:00 p.m. each day, overnight-fasted plasma 
quercetin levels were 36% and 62% greater than the 
presupplementation levels in the Q and Q–EGCG groups, 
respectively, compared with a 24% decrease in P (Fig. 1). 
After the third day of exercise, plasma quercetin levels at 
6:00 p.m. (i.e., 4 h after the last supplement dose) were 
221% and 364% greater than the presupplementation levels 
in the Q and Q–EGCG groups, respectively. At 14 h after 
exercise, a significant 111% increase in plasma quercetin 
levels was measured in the Q–EGCG group. 
Total blood leukocytes tended to be lower after exer- 
cise in the Q and Q–EGCG groups compared with P (both 
 
 
 
FIGURE 2—Serum CRP before and after 2 wk of supplementation 
and immediately and 14 h after exercise. Group x time interaction 
P value = 0.023. *P G 0.05, change from before supplementation 
compared with placebo. 
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FIGURE 3—Plasma IL-6 before and after 2 wk of supplementation 
and immediately and 14 h after exercise. Group x time interaction 
P value = 0.021. *P G 0.05, change from before supplementation 
compared with placebo. 
 
 
P = 0.094), with significantly lower levels 14 h after exer- 
cise (Table 2). No significant group differences were found 
after 2 wk of supplementation or after exercise for CK, the 
ratio of sIgA to protein, or MPO. 
Serum CRP was 50% less than P in the Q–EGCG group 
both immediately after exercise on the third day and 14 h after 
exercise (interaction P value = 0.023; Fig. 2). Plasma IL-6 
was 39% less than P in the Q–EGCG group immediately 
after exercise (interaction P value = 0.021; Fig. 3). Plasma 
G-CSF was 25% less than P in the Q–EGCG group imme- 
diately after exercise (P = 0.087), with significant decreases 
measured in Q (31%) and Q–EGCG (39%) 14 h after 
exercise (Table 3). Plasma IL-10 was significantly less than 
P levels immediately after exercise in both Q and Q–EGCG 
groups (Table 3). Plasma MCP tended to be lower than P 
immediately after exercise in the Q–EGCG group (15%, 
 
 
 
FIGURE 4—GOBA before and after 2 wk of supplementation and 
immediately and 14 h after exercise. Group x time interaction P value = 
0.168. *P G 0.05, change from before supplementation compared with 
placebo. 
TABLE 4. Muscle mRNA expression for PGC-1>, cytochrome c oxidase, and citrate 
synthase. 
 
 
Variable 
Before 
Supplementation 
 
After  Supplementation 
 
PGC-1> 
P 
 
1 
 
1.01 T 0.05 
 
0.337 
Q 1 1.00 T 0.02  
Q–EGCG 1 0.94 T 0.03  
Cytochrome c    
P 1 1.13 T 0.08 0.335 
Q 1 1.08 T 0.05  
Q–EGCG 1 1.29 T 0.15  
Citrate synthase    
P 1 1.01 T 0.08 0.440 
Q 1 1.06 T 0.06  
Q–EGCG 1 0.93 T 0.05  
P value represents one-way ANOVA F probability comparing after supplementation. 
Data are expressed as fold change from before supplementation (set as 1); n = 6 for 
each group. 
 
 
P = 0.060). Groups did not differ at any time points for plasma 
IL-1RA, TNF->, and HSP-70 (Table 3). Figure 4 shows that 
granulocyte oxidative burst activity (GOBA) was signifi- 
cantly elevated greater than that in P after 2 wk of supple- 
mentation in the Q–EGCG group, with no group differences 
in measures after exercise (interaction P value = 0.168). 
Table 4 summarizes skeletal muscle mRNA expression 
data for three genes related to mitochondrial biogenesis 
(n = 6 per group), with no differences measured between 
groups after 2 wk of supplementation or after exercise. 
Figure 5 shows that DOMS scores were significantly 
reduced 2 and 3 d after the 3-d cycling sessions in Q, with 
scores tending to be lower in the Q–EGCG group on these 
same 2 d (P = 0.158 and P = 0.104, respectively). 
 
 
DISCUSSION 
The exercise-induced changes in immune and inflamma- 
tion outcome measures reported in this study are similar to 
 
 
 
FIGURE 5—DOMS at the end of the third 3-h cycling bout and during 
1 wk of follow-up. Group x time interaction P value = 0.252. *P G 0.05, 
change from before supplementation compared with placebo. 
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what we have previously reported under similar  condi- 
tions (28,30,31). The data from this study indicate that a 
quercetin supplement combined with EGCG, isoquercetin, 
EPA, and DHA is more effective than a placebo or 
quercetin supplement without these added components in 
elevating plasma quercetin and countering exercise-induced 
inflammation. The Q–EGCG supplement also increased 
GOBA after 2 wk of supplementation relative to placebo 
but did not counter the exercise-induced drop in this 
measure after 3 d of 3-h cycling bouts. Cycling time trial 
performance at the end of the 3-h cycling bouts or mRNA 
expression for genes related to skeletal muscle mitochon- 
drial biogenesis did not differ between groups. DOMS 2 
and 3 d after exercise tended to be lower in both quercetin 
groups compared with placebo. 
In a previous study conducted by our research team using 
a similar exercise regimen, quercetin (1000 mgIdj1 in a 
Tang beverage, 8:00 a.m. and 6:00 p.m. dosing) ingestion 
by cyclists for 3 wk did not alter exercise-induced increases 
in measures of inflammation and oxidative stress or alter- 
ations in  immune outcomes (23,30,31).  A second 3-wk 
quercetin supplementation study with ultramarathon runners 
at the 160-km Western States Endurance Run (WSER) 
produced similar null results when compared with placebo 
(15,29). At the WSER, subjects ingested 1000 mg of 
quercetin or placebo supplements just before the 160-km 
race (5:00 a.m.) but did not ingest additional supplements 
until after postrace blood samples were acquired (an 
average of 27 h later). Plasma quercetin levels dropped to 
very low levels in the quercetin group and were not much 
different from the placebo group after the race. 
These results led us to reevaluate the literature on the 
bioavailability and half-life of quercetin. A recent quercetin 
pharmacokinetics study suggests that the average terminal 
half-life of quercetin may be as low as 3.5 h (25), but most 
other studies indicate a range of 11–28 h (22). Additional 
literature indicates that isoquercetin is more completely 
absorbed than is quercetin  in  aglycone  form  and  that 
the simultaneous ingestion of quercetin with vitamin C, 
folate, and additional flavonoids improves bioavailability 
(14,22,24). The glucose molecule in isoquercetin may favor 
the use of the sodium-dependent glucose transport pathway 
of the intestinal brush border membrane, improving 
absorption rates when compared with the pure aglycone 
form of quercetin (37). Two or more flavonoids ingested 
together may increase bioavailability and decrease elimina- 
tion via competitive inhibition of glucuronide and sulfate 
conjugation in both the intestine and the liver and via 
inhibition of efflux transporters such as P-glycoprotein, 
breast cancer resistance protein, and multidrug resistance 
protein 2 (24). Quercetin’s anti-inflammatory effects may 
be augmented by coingestion of N3-PUFA (4), vitamin C, 
and EGCG (16). For example, the concurrent administration 
of EPA, DHA, and quercetin resulted in a synergistic anti- 
inflammatory effect in rats with intestinal inflammatory 
disorders (4). In vitro data indicate that quercetin exhibits 
antiviral activity only when protected against oxidative 
degradation by ascorbate (36). 
The Q–EGCG supplement was formulated to improve the 
bioavailability and bioactive effects of quercetin, and the 
research design was changed to emphasize ingestion of half 
the daily dose 1 h before heavy exertion. The quercetin 
supplement (without added components) was related to 
some effects that we previously did not find, including a 
decrease in total blood leukocytes and G-CSF the morning 
after 3 d of heavy exertion, a reduction in plasma IL-10 
after exercise, and a lowered DOMS 2 and 3 d afterward. 
These effects may have been related to the 8:00 a.m. and 
2:00 p.m. dosing regimen (compared with 8:00 a.m. and 
6:00 p.m. or immediately after exercise in our previous 
study) (23,30,31). The Q–EGCG supplement produced 
more widespread effects on inflammation (in particular, 
reduced CRP and IL-6). These effects may have been 
related to the coingestion of quercetin with isoquercetin, 
EGCG, EPA, and DHA (4,16,24). The morning after the 
3-d period of intensified exercise, plasma quercetin levels in 
Q–EGCG were elevated 98% greater than that in placebo 
and 54% (P = 0.06) greater than that in Q, thus supporting 
the concept of a more prolonged quercetin effect from inges- 
tion of the quercetin cocktail supplement. 
No group differences were measured for cycling time 
trial performance (after a substantial exercise preload) or 
mRNA expression for three genes related to muscle 
mitochondrial biogenesis. One study of 11 elite male 
cyclists reported a 1.7% 30-km time trial performance 
enhancement greater than placebo after 6 wk of quercetin 
supplementation (21). This study used a randomized, 
double-blinded, crossover design, and the exercise regimen 
used a mountainous terrain format without an exercise 
preload. Another study using sedentary mice showed that 
7 d of quercetin feeding (both 12.5 and 25 mgIkgj1) 
increased cytochrome c concentration and citrate synthase 
activity in soleus muscle by 20%–30% (8). Quercetin 
feedings also increased treadmill run time to fatigue by 
approximately 30%, with both quercetin doses equally 
effective. Together, these data suggest that quercetin may 
have a larger effect on untrained muscle, which has a lower 
mitochondrial density than in trained muscle. The data from 
available studies suggest that if a muscle mitochondrial 
biogenesis and performance effect exists in endurance 
athletes, quercetin supplementation may have to be 6 wk 
or longer, and the magnitude may be well below what could 
be measured in untrained subjects. 
In summary, a quercetin supplement combined with 
EGCG, isoquercetin, and N3-PUFA was more  effective 
than quercetin without these added components in  par- 
tially countering exercise-induced inflammation but with- 
out effects on cycling time trial performance or muscle 
mitochondrial biogenesis compared with placebo. These 
data add to the growing literature support for the concept 
that quercetin’s anti-inflammatory effects are amplified 
when coingested with other flavonoids, food components, 
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and micronutrients. Additional research is needed to 
determine whether the proportions and  amounts  used  in 
this study (i.e., 1000 mg of aglycone quercetin, 400 mg of 
isoquercetin, 120 mg of EGCG, 400 mg of N3-PUFA) are 
optimal and whether additional food components might add 
to the effects measured in this study. The duration of 
supplementation used in this study (2 wk before intensified 
exercise) was based in part on  quercetin  pharmacokinetic 
data and findings from animal studies (8,22,24), but Q– 
EGCG’s countermeasure effects may benefit from a more 
prolonged supplementation period. Cycling induces less 
muscle damage, inflammation, and oxidative stress than 
running, and findings reported in this study on cyclists may 
differ in magnitude from those measured in competitive 
marathon runners. 
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